Edurant (Rilpivirine, TMC278): News & Research
- Labeling Updates for Edurant (Rilpivirine) (January 3, 2013)
From U.S. Food and Drug Administration
- Switching to Rilpivirine/Tenofovir/FTC Fixed-Dose Combination From Boosted-PI Regimen: SPIRIT Study Draws the Line at 24 Weeks (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Early Data for Rilpivirine Long-Acting Formulation Supports Further Investigation for PrEP (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Studies on Pipeline Antiretrovirals Reveal New Data on Possible Drug Interactions (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Similar Efficacy and a Few Gender-Related Differences in Side Effects With Rilpivirine Versus Efavirenz at 96 Weeks (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Conference Update From IAS 2011: Medication News (September/October 2011)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- FDA Approve New NNRTI Rilpivirine (Edurant) in the U.S. (July/August 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Edurant and Sustiva Similar, With Some Failure and Safety Differences, in Two-Year Studies (July 21, 2011)
From AIDSmeds.com
- A New HIV Drug Called Edurant Gets Approved for First-Time Patients (May 20, 2011)
From Project Inform
- FDA Approves Edurant (Rilpivirine) for Use in Treatment-Naive Adults With HIV-1 (May 20, 2011)
From Tibotec Therapeutics
- Approval of Edurant (Rilpivirine), a New NNRTI, for the Treatment of HIV in Treatment-Naive Patients (May 20, 2011)
From U.S. Food and Drug Administration
- MSF Letter Criticizes Johnson & Johnson for Not Joining Medicines Patent Pool (April 26, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Gilead Says FDA Won't Accept Filing for AIDS Pill (February 3, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Johnson & Johnson Deal May Bring HIV/AIDS Drugs to Developing Countries Faster (January 31, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Gilead Sciences Receives "Refuse to File" Notification From U.S. FDA on New Drug Application for Single-Tablet Regimen of Truvada and TMC278 (January 25, 2011)
From Gilead Sciences, Inc.
- Rilpivirine: The New NNRTI on the Block (December 8, 2010)
Part of "Top HIV/AIDS-Related Clinical Developments of 2010," by David Wohl, M.D.
From TheBody.com
- Rilpivirine vs. Efavirenz (October 25, 2010)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
- Update: 2010 International AIDS Conference (September/October 2010)
Tales from Vienna: The world's AIDS community converges upon Vienna for the International AIDS Conference.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- TMC-278 Phase 3 ECHO/THRIVE Studies Resistance Profile Rilpivirine (September 15, 2010)
From National AIDS Treatment Advocacy Project
- Rilpivirine Shows Potent Activity (Summer/Fall 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- TMC278 (Rilpivirine) Stands Up to Efavirenz in Battle of First-Line NNRTIs; FDA Approval May Be Drawing Near: A Blog Entry by Myles Helfand (July 28, 2010)
In The XVIII International AIDS Conference, from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
